Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia

Clinical Infectious Diseases

Volumn 46, Issue 1, 2008, Pages 30-36

  Erlandson, Kristine Mace ^a   Sun, Junfeng ^b   Iwen, Peter C ^a   Rupp, Mark E ^a,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMPICILLIN; CHLORAMPHENICOL; CILASTATIN PLUS IMIPENEM; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; LINEZOLID; PENICILLIN G; RIFAMPICIN; TETRACYCLINE DERIVATIVE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG POTENCY; ENTEROCOCCAL INFECTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; TIME SERIES ANALYSIS; UNIVARIATE ANALYSIS;

ACETAMIDES; ADULT; ANTI-BACTERIAL AGENTS; BACTEREMIA; ENTEROCOCCUS; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; OXAZOLIDINONES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VANCOMYCIN RESISTANCE; VIRGINIAMYCIN;

EID: 39349084481     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/523588     Document Type: Article

References (28)

1. Leclerq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988; 319:157-61.
2. Centers for Disease Control and Prevention. Nosocomial enterococci resistant to vancomycin - United States, 1989-1993. MMWR Morb Mortal Wkly Rep 1993; 42:597-9.
3. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 1993; 6:428-42.
4. Papanicolaou GA, Meyers BR, Meyers J, et al. Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: risk factors for acquisition and mortality. Clin Infect Dis 1996; 23:760-6.
5. Vergis EN, Hayden MK, Chow JW, et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. Ann Intern Med 2001; 135:484-92.
6. Lucas GM, Lechtzin N, Puryear DW, Yau LL, Flexner CW, Moore RD. Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes. Clin Infect Dis 1998; 26:1127-33.
7. Lautenbach E, Bilker WB, Brennan PJ. Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality. Infect Control Hosp Epidemiol 1999; 20:318-23.
8. Gearhart M, Martin J, Rudich S, et al. Consequences of vancomycin-resistant Enterococcus in liver transplant recipients: a matched control study. Clin Transplant 2005; 19:711-16.
9. Garbutt JM, Ventrapragada M, Littenberg B, Mundy LM. Association between resistance to vancomycin and death in cases of Enterococcus faecium bacteremia. Clin Infect Dis 2000; 30:466-72.
10. Stroud L, Edwards J, Danzig L, Culver D, Gaynes R. Risk factors for mortality associated with enterococcal bloodstream infections. Infect Control Hosp Epidemiol 1996; 17:576-80.
11. Edmond MB, Ober FJ, Weinbaum DL, et al. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis 1995; 20:1126-33.
12. Shay DK, Maloney SA, Montecalvo M, et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 1995; 172:993-1000.
13. Lodise TP, McKinnon PS, Tam VH, Ryback MJ. Clinical outcomes for patients with bacteremia caused by vancomycin-resistant Enterococcus in a level 1 trauma center. Clin Infect Dis 2002; 34:922-9.
14. Linden PK, Pasculle AW, Manez R, et al. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis 1996; 22:663-70.
15. Winston DJ, Emmanouilides C, Kroeber A, et al. Quinupristin/dalfopristin therapy for infections due to vancomycin-resistant Enterococcus faecium. Clin Infect Dis 2000; 30:790-7.
16. Moellering RC, Linden PK, Reinhardt J, Blumberg EA, Bompart F, Talbot GH. The efficacy and safety of quinupristin/dalfopristin (Synercid) for the treatment of infections cause by vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother 1999; 44:251-61.
17. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 2003; 36:159-68.
18. Segreti JA, Crank WC, Finney MC. Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients. Pharmacotherapy 2006; 26:347-352.
19. Kasbekar N. Tigecycline: a new glycylcline antimicrobial agent. Am J Health Syst Pharm 2006; 63:1235-43.
20. Chow JW, Fine MJ, Shlaes DM, et al. Enterococcus bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 115:585-91.
21. Noskin GA, Peterson LR, Warren JR. Enterococcus faecium and Enterococcus faecalis bacteremia: acquisition and outcome. Clin Infect Dis 1995; 20:296-301.
22. Altmann DG. Practical statistics for medical research. London: Chapman & Hall/CRC Press, 1991.
23. Hosmer DW, Lemeshow S. Applied logistic regression, 2nd ed. New York: John Wiley, 2000.
24. Mermel LA, Maki DG. Detection of bacteremia in adults: consequences of culturing an inadequate volume of blood. Ann Intern Med 1993; 119:270-2.
25. Arabi Y, Abbasi A, Goraj R, et al. External validation of a modified model of acute physiology and chronic health evaluation (APACHE) II for orthotopic liver transplant patients. Crit Care 2002; 6:245-50.
26. Herrero IA, Issa NC, Patel N. Nosocomial spread of LZD-resistant, vancomycin-resistant Enterococcus faecium. N Engl J Med 2002; 346:867-9.
27. Chow JW, Donahedian SM, Zervos MJ. Emergence of increased resistance to QPD during therapy for Enterococcus faecium bacteremia. Clin Infect Dis 1997; 24:90-1.
28. Long JK, Choueiri TK, Hall GS, Avery RK, Sekeres MA. Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia. Mayo Clin Proc 2005; 80:1215-6.